Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287897 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT01287897 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 250 participants.
The verdict
NCT01287897, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a proof of concept study to determine the efficacy and safety of a monoclonal antibody with three doses versus placebo. Subjects will be randomized to a treatment and the dose will be delivered subcutaneously twice, 4 weeks apart. All subjects will have moderate to severe refractory Crohn's Disease.
Interventions
- DRUG PF-04236921 SC injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01287897
The ClinicalTrials.gov registry entry for NCT01287897 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04236921 SC injection is the first listed.
NCT01287897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01287897 about?
NCT01287897 is a clinical study titled "A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy". This is a proof of concept study to determine the efficacy and safety of a monoclonal antibody with three doses versus placebo. Subjects will be randomized to a treatment and the dose will be delivered subcutaneously twice, 4 weeks apart. All subjects will have moderate to severe refractory Crohn's ...
What is the current status of trial NCT01287897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2011-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01287897?
The interventions under investigation include: PF-04236921 SC injection (DRUG).
Who is sponsoring clinical trial NCT01287897?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.